Ding PN, et al. – Author's purpose is to portray clinical characteristics, treatment patterns and factors influencing outcomes in patients with EGFR–mutated non–small cell lung cancer (NSCLC) in SWSLHD. Results from this community–based cohort affirm known prognostic factors in patients with EGFR–mutated NSCLC receiving tyrosine kinase inhibitors and propose the negative impact of a heightened host systemic inflammatory response on patient results.